Global Human Microbiome Therapeutics Market 2018-2022
About Human Microbiome Therapeutics
Microbiome Therapeutics is developing evidence-based microbiome modulators designed to shift bacterial populations and their environment in the gastrointestinal (GI) tract to better manage serious health conditions. GIT is an organ system that includes the mouth, esophagus, stomach, and the intestines. The GIT can be divided into upper Git and lower GIT. Upper GIT consists of the oral cavity, the pharynx, the esophagus, the stomach, and the duodenum. The lower GIT consists of the small and large intestines. Gastrointestinal disorders refer to diseases involving the GIT. Microbiome therapeutics are being increasingly adopted for the treatment of gastrointestinal disorders such as IBS and ulcerative colitis.
Technavio’s analysts forecast the global human microbiome therapeutics market to grow at a CAGR of 14.19% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global human microbiome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of human microbiome therapeutics.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Human Microbiome Therapeutics market 2018-2022
Technavio recognizes the following companies as the key players in the global human microbiome therapeutics market: ENTEROME Bioscience, Rebiotix, Seres Therapeutics, and Vedanta Biosciences.
Other Prominent Vendors in the market are: Bristol-Myers Squibb, Johnson & Johnson, and Takeda Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is growing investments from venture capitalists. Venture capitalists are capitalizing on the need for effective treatment and are offering therapeutic treatment solutions to treat disorders such as autoimmune disorders, infections, and cancer. Investments from venture capitalists towards microbiome therapeutics is exponentially boosting the growth of the microbiome sequencing therapeutics market. Vedanta Biosciences is already collaborating with NYU Langone Medical Center to develop novel microbiome- derived immunotherapies for cancer patients.”
According to the report, one of the major drivers for this market is side effects of the existing treatments. Various medicines available in the market have several side-effects including minor headaches. These medicines may also impart serious side-effects such as liver or kidney injury, heart problems, and even death. The seriousness of side-effects drives the need for innovative treatment technologies, such as human microbiome therapeutics, that have reduced the negative impact on the human body. The demand for microbiome therapeutics is increasing since it provides treatment sans chemicals.
ENTEROME Bioscience, Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb, Johnson & Johnson, and Takeda Pharmaceutical.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook